Proliferation Parameters for Pituitary Adenomas

Acta Neurochirurgica, Supplement

Volumn 1996, Issue 65, 1996, Pages 18-21

  Buchfelder, M ^a,b   Fahlbusch, R ^a   Adams, E F ^a   Kiesewetter, F ^a   Thierauf, P ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Flow cytometry; Immunohistochemistry; Invasion; Pituitary adenomas; Proliferation; Transsphenoidal surgery

Indexed keywords

TUMOR MARKER;

ADENOMA; BIOPSY; CANCER INVASION; CELL DIVISION; ECTOPIC HORMONE PRODUCTION; HUMAN; HYPOPHYSECTOMY; HYPOPHYSIS; HYPOPHYSIS TUMOR; PATHOLOGY; PHYSIOLOGY; REVIEW;

ADENOMA; BIOPSY; CELL DIVISION; HUMANS; HYPOPHYSECTOMY; NEOPLASM INVASIVENESS; PARANEOPLASTIC ENDOCRINE SYNDROMES; PITUITARY GLAND; PITUITARY NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0029689792     PISSN: 00651419     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-9450-8_7     Document Type: Article

References (20)

1. Anniko M, Wersäll J (1988) DNA studies for prediction of prognosis of pituitary adenomas. Adv Biosci 69: 45-52
2. Buchfelder M, Adams EF, Honegger J, Fahlbusch R (1989) DNA polymerase activity in human pituitary adenomas. J Endocrinol Invest 12 [Suppl 2]: 44
3. Chatterjee S, May PL, Forster G, Spiller D, Jeffreys RV (1993) Prediction of recurrence in pituitary tumours: a flow cytometric study using in vivo bromodeoxyuridine. Br J Neurosurg 7: 165-170
4. Deshmukh P, Ramsey L, Garewal HS (1990) Ki-67 labeling index is a more reliable measure of solid tumor proliferative activity than tritiated thymidine labeling. Am J Clin Pathol 94: 192-195
5. Edwards DW, Murthy SR, McGuire WL (1980) Effects of estrogen and antiestrogen on DNA polymerase in human breast cancer. Cancer Res 40: 1722-1726
6. Fitzgibbons PL, Appley AJ, Turner RR, Bishop PC, Parker JW, Breeze RE, Weiss MH, Apuzzo MLJ (1988) Flow cytometric analysis of pituitary tumors. Correlation of nuclear antigen p105 and DNA content with clinical behaviour. Cancer 62: 1556-1560
7. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715
8. Hsu DW, Hakim F, Biller BMK, De la Monte S, Zervas NT, Klibanski A, Hedley-Whyte T (1993) Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg 78: 753-761
9. Jefferson G (1952) The invasive adenomas of the anterior pituitary. Thomas, Springfield
10. Knosp E, Kitz K, Perneczky A (1989) Proliferation activity in pituitary adenomas: Measurement by monoclonal antibody Ki-67. Neurosurgery 25: 927-930
11. Kovacs K, Horvath E (1986) Tumors of the pituitary gland. Armed Forces Institute of Pathology, Washington
12. Landolt AM, Shibata T, Kleihues P (1987) Growth rate of human pituitary adenomas. J Neurosurg 67: 803-806
13. 3H] thymidine into rat pituitary tumor cells. Brain Res 369: 83-90
14. Nagashima T, Murovic JA, Hoshino T, Wilson CB, DeArmond SJ (1986) The proliferative potential of human pituitary adenomas in situ. J Neurosurg 64: 588-593
15. Scanarini M (1993) Octeotide therapy of GH-secreting adenomas: histologic and cytological aspects. J Endocrinol Invest 16: 453-454
16. Scheithauer BW, Kovacs KT, Laws ER, Randall RV (1986) Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 65: 733-744
17. Selman WR, Laws ER, Scheithauer BW, Carpenter SM (1986) The occurrence of dural invasion in pituitary adenomas. J Neurosurg 64: 402-407
18. Shaffi OM, Wrightson P (1975) Dural invasion by pituitary adenomas. N Z Med J 81: 386-390
19. Shibuya M, Saito F, Miwa T, Davis RL, Wilson CB, Hoshino T (1992) Histochemical study of pituitary adenomas with Ki-67 and anti-DNA polymerase a monoclonal antibodies, bromodeoxyuridine labeling, and nuclear organizer region counts. Acta Neuropathol 84: 178-183
20. Wiklund JA, Gorski J (1982) Genetic differences in estrogeninduced deoxyribonucleic acid synthesis in the rat pituitary: Correlations with pituitary tumours susceptibility. Endocrinology 111: 1140-1149